Ahmedabad: Chemical manufacturer Epigral Limited reported a 26% YoY increase in profit after tax (PAT) to Rs 64 crore for the Sept quarter of FY27, against Rs 51 crore in the year-ago period. The company’s revenue from operations rose 28% to Rs 752 crore, compared with Rs 589 crore in the corresponding quarter last year. The growth came on the back of a 6% increase in sales volumes and improved realisations.However, higher raw material costs weighed on operating profitability. Even though Epigral Limited’s EBITDA increased marginally by 3% to Rs 136 crore, its EBITDA margin declined to 18%.The company’s derivatives and specialty chemicals business contributed 57% of revenue during the quarter, up from 50% in the year-ago period, signalling its rising focus on high-value chemical products.On the expansion front, the company spent Rs 88 crore on capital expenditure during H1FY27. Its additional CPVC resin capacity of 75,000 tonnes per annum (TPA) and epichlorohydrin capacity of 50,000TPA are expected to be commissioned in Q3FY27. The expansions will take total CPVC resin capacity to 1.5 lakh TPA and epichlorohydrin capacity to 1 lakh TPA.The company’s board has also approved two projects at its Dahej manufacturing complex: an epoxy resin and formulations plant with an annual capacity of 1.25 lakh tonnes, and a multi-purpose downstream plant. Both projects are expected to be commissioned in the second half of FY28.Chairman and managing director Maulik Patel said, “The company expects stronger performance in the second half of FY27, which traditionally contributes more to its annual business. The quarter’s revenue growth is a function of higher volumes and improved realisations, while acknowledging the impact of elevated raw material prices on margins.”
